Monitoring of Lipids in Diabetes
Abstract
Dyslipidemia should be monitored regularly in diabetes mellitus and the assessment should include the measurement of total cholesterol, high-density lipoprotein cholesterol, and triglyceride concentrations. More detailed investigations may be required if a primary hyperlipoproteinemia is suspected and other causes of secondary hyperlipidemia should be considered. Several physiological factors cause variation in serum lipid concentrations, including age, sex, the menstrual cycle, and diet. Posture, venepuncture technique, concomitant medication, and clinical conditions other than diabetes mellitus also affect lipid levels. This chapter will consider the investigations that are used widely in clinical practice and sources of variation in lipoprotein metabolism.
References
- 1 Laker MF, Game FL. Approaches to lipid and lipoprotein analysis. Clin Endocrinol Metab 1990; 4: 693–717.
- 2 CA Converse, ER Skinner (eds), Lipoprotein Analysis. A Practical Approach. Oxford: IRL Press, 1992.
- 3 Laker MF, Game FL. Laboratory investigations of dyslipoproteinaemias. In DJ Betteridge, DR Illingworth, J Shepherd (eds), Lipoproteins in Health and Disease. London: Edward Arnold, 1999; pp 381--98.
- 4
Stein E.
Clinical chemistry annual review.
Curr Opin Lipidol
1991;
2:
341–91.
10.1097/00041433-199112000-00001 Google Scholar
- 5
Stein EA,
Myers GL.
Clinical chemistry—annual review.
Curr Opin Lipidol
1992;
3:
359–98.
10.1097/00041433-199212000-00001 Google Scholar
- 6
Assmann G,
Hunt BJ.
Clinical chemistry—annual review.
Curr Opin Lipidol
1993;
4:
425–94.
10.1097/00041433-199312000-00002 Google Scholar
- 7 Steiner C. Atherosclerosis, the major complication of diabetes. Adv Exp Med Biol 1985; 189: 277–97.
- 8Panzram G. Mortality and survival in type 2 (noninsulin dependent) diabetes mellitus. Diabetologia 1987; 30: 123–31.
- 9 Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). Br Med J 1998; 316: 823–8.
- 10 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
- 11 Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–97.
- 12 Hanefield M, Schulze J, Fischer S, Julius U, Schmechel H, Haller H. The diabetes intervention study (DIS). A co-operative multi-intervention trial with newly manifest type 2 diabetes. Monogr Atheroscler 1985; 13: 98–103.
- 13 Kannel WB, McGee DL. Diabetes and cardiovascular disease. J Am Med Assoc 1979; 241: 2035–8.
- 14 Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. J Am Med Assoc 1990; 263: 2893–8.
- 15 Heyden S, Heiss G, Bartel AG, Hames CG. Sex differences in coronary mortality among diabetics in Evans County, Georgia. J Chronic Dis 1980; 33: 265–73.
- 16 West KM, Ahuja MMS, Bennett PA, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RK, Kosaka K. The role of circulating glucose and triglyceride concentrations and their interaction with other risk factors as determinants of arterial disease in nine diabetic populations from the WHO multinational study. Diabetes Care 1983; 6: 361–9.
- 17 Fontbonne A, Eschwège E, Cambien F, Richard J-L, Ducimetière P, Thibult N, et al.Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 1989; 32: 300–4.
- 18
Austin MA,
King MV,
Vranizan KM,
Krauss RM.
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease.
Circulation
1990;
82:
592–5.
10.1161/01.CIR.82.2.495 Google Scholar
- 19 Stewart MW, Laker MF, Dyer RG, Game FL, Mitcheson J, Winocour PH, Alberti KGMM. Lipoprotein compositional abnormalities and insulin resistance in type 2 diabetic patients with mild hyperlipidaemia. Arterioscler Thromb 1993; 13: 1046–52.
- 20 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
- 21 Inzucchi SE, Amatruda JM. Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care 2003; 26: 1309–11.
- 22 Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26 (suppl 1): S83–6.
- 23 Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733–7.
- 24 European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999; 16: 716–30.
- 25 Department of Health (UK). National service framework for coronary heart disease, 2001. Available at: http://www.doh.gov.uk/nsf/coronary.htm. Accessed September 15, 2003.
- 26 British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (2S): 1S–29S.
- 27 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9.
- 28 Wagner AM, Perez A, Calvo F, Bonet R, Castellvi A, Ordonez J. Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. Diabetes Care 1999; 22: 812–7.
- 29 Rubies-Prat J, Reverter JL, Senti M, Pedro-Botet J, Salinas I, Lucas A, Nogues X, Sanmarti A. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993; 16: 1081–6.
- 30 Durrington PN. Can measurement of apolipoprotein B replace the lipid profile in the follow-up of patients with lipoprotein disorders? Clin Chem 2002; 48: 401–2.
- 31 Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453–60.
- 32 Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, deCani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477–84.
- 33 Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, Forrester J, Herd JA, Hoogwerf B, Campeau L, Gobel FL. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis 1999; 146: 369–79.
- 34 Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447–59.
- 35 Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106: 2526–9.
- 36 Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413–9.
- 37 Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106: 2537–42.
- 38 Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care 2003; 26: 16–23.
- 39 Hsia SH. Non-HDL cholesterol: into the spotlight. Diabetes Care 2003; 26: 240–2.
- 40 Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, et al.Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37–45.
- 41 Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153–69.
- 42
Richmond WR.
Analytical reviews in clinical biochemistry: the quantitative analysis of cholesterol.
Ann Clin Biochem
1992;
9:
577–97.
10.1177/000456329202900601 Google Scholar
- 43 Warnick GR. Compact analysis systems. Curr Opin Lipidol 1991; 2: 343–8.
- 44 Klotzsch SG, McNamara JR. Triglyceride measurements: a review of methods and interferences. Clin Chem 1990; 36: 1605–13.
- 45 Jessen RH, Dass CJ, Eckfeldt JH. Do enzymatic analyses of serum triglycerides really need blanking for free glycerol? Clin Chem 1990; 36: 1372–5.
- 46 Naito HK, David JA. Laboratory considerations: determination of cholesterol, triglyceride, phospholipid, and other lipids in blood and tissues. In JA Storey (ed), Lipid Research Methodology. New York: Alan R Liss, 1984; pp 1–76.
- 47 Stewart MW, Laker MF, Alberti KGMM. Effects of self-monitoring of triglyceride concentrations in noninsulin dependent diabetes mellitus. Br Med J 1993; 306: 493.
- 48 Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogenous assays. Clin Chem 2001; 47: 1579–96.
- 49 Myers GL, Copper GR, Henderson LO, Hassemer DJ, Kimberley MM. Standardisation of lipid and lipoprotein measurement. In N Rifai, GR Warnick, MH Dominiczak (eds), Handbook of Lipoprotein Testing. Washington: AACC Press, 2000; pp 717–48.
- 50 Nauck M, März W, Jarausch J, Cobbaert C, Sägers A, Bernard D, Delanghe J, Honauer G, Lehmann P, Oestrich E, vonEckardstein A, Walch S, Wieland H, Assmann G. Multicenter evaluation of a homogenous assay for HDL-cholesterol without sample pretreatment. Clin Chem 1997; 43: 1622–9.
- 51 Lackner KJ, Schmitz G. β-VLDL of patients with Type III hyperlipoproteinemia interferes with homogenous determination of HDL-cholesterol based on polyethylene glycol-modified enzymes. Clin Chem 1998; 44: 2546–8.
- 52 Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, Wilson PW. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002; 25: 989–94.
- 53 The Lipid Research Clinics Coronary Primary Prevention Trial results, I: Reduction in incidence of coronary heart disease. J Am Med Assoc 1984; 251: 351–64.
- 54 Cole TG, Ferguson CA, Gibson DW, Nowatzke WL. Optimization of beta-quantification methods for high-throughput applications. Clin Chem 2001; 47: 712–21.
- 55 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
- 56 Senti M, Pedro-Botet J, Nogués X, Rubies-Prat J. Influence of intermediate-density lipoproteins on the accuracy of the Friedewald formula. Clin Chem 1991; 37: 1394–7.
- 57 Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990; 36: 15–9.
- 58 Branchi A, Rovellini A, Torri A, Sommariva D. Accuracy of calculated serum low-density lipoprotein cholesterol for the assessment of coronary heart disease risk in NIDDM patients. Diabetes Care 1998; 21: 1397–402.
- 59 Planella T, Cortes M, Martinez-Bru C, Gonzalez-Sastre F, Ordonez-Llanos J. Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. Clin Chem 1997; 43: 808–15.
- 60 Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002; 48: 236–54.
- 61 Usui S, Kakuuchi H, Okamoto M, Mizukami Y, Okazaki M. Differential reactivity of two homogeneous LDL-cholesterol methods to LDL and VLDL subfractions, as demonstrated by ultracentrifugation and HPLC. Clin Chem 2002; 48: 1946–54.
- 62 Miller WG, Waymack PP, Anderson FP, Ethridge SF, Jayne EC. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem 2002; 48: 489–98.
- 63 Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94: 273–8.
- 64 Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–33.
- 65 Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF, Case RB. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 2517–22.
- 66 van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van derWall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000; 20: 2408–13.
- 67 Grundy SM. Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Arch Intern Med 2001; 161: 1379–80.
- 68 Sniderman AD, Lamarche B, Tilley J, Seccombe D, Frohlich J. Hypertriglyceridemic hyperapoB in type 2 diabetes. Diabetes Care 2002; 25: 579–82.
- 69 Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Clin Chem 1991; 37: 1676–82.
- 70 Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, III: Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993; 39: 773–81.
- 71 Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV: Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994; 40: 586–92.
- 72 Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, II: Evaluation and selection of candidate reference materials. Clin Chem 1992; 38: 658–62.
- 73 Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 507–14.
- 74 Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996; 42: 515–23.
- 75 Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and A-I distributions in the United States, 1988–1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997; 43: 2364–78.
- 76 Jungner I, Marcovina SM, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998; 44: 1641–9.
- 77 Miremadi S, Sniderman A, Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders? Clin Chem 2002; 48: 484–8.
- 78 Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777–80.
- 79 Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In CR Scriver, AL Beaudet, WS Sly, D Valle (eds), The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995; pp 1953–80.
- 80 Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002; 48: 278–83.
- 81 Marcoux C, Tremblay M, Fredenrich A, Jacques H, Krimbou L, Nakajima K, Davignon J, Cohn JS. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis 1998; 139: 161–71.
- 82 Ooi TC, Cousins M, Ooi DS, Steiner G, Uffelman KD, Nakajima K, Simo IE. Postprandial remnant-like lipoproteins in hypertriglyceridemia. J Clin Endocrinol Metab 2001; 86: 3134–42.
- 83 Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, Wilson PW, for the Framingham Offspring Study. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002; 25: 989–94.
- 84 Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999; 99: 2852–4.
- 85 Stein DT, Devaraj S, Balis D, Adams-Huet B, Jialal I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2001; 21: 2026–31.
- 86 Karpe F, Taskinen MR, Nieminen MS, Frick MH, Kesaniemi YA, Pasternack A, Hamsten A, Syvanne M. Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis 2001; 157: 181–7.
- 87 Jialal I, Devaraj S. Remnant lipoproteins: measurement and clinical significance. Clin Chem 2002; 48: 217–9.
- 88 Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999; 19: 2474–86.
- 89 Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al.Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gel. Clin Chim Acta 1993; 223: 53–71.
- 90 Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, Nakajima K, Havel RJ. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 1998; 44: 2490–8.
- 91 Laboratory Standardization Panel. Current status of blood cholesterol measurements in the United States: a report from the Laboratory Standardization Panel of the National Cholesterol Education Program. Clin Chem 1988; 34: 193–201.
- 92 Boerma GJM, Jansen AP, Jansen RTP, Leijnse B, vanStrik R. Minimizing interlaboratory variation in routine assays of serum cholesterol through the use of serum calibrators. Clin Chem 1986; 32: 943–7.
- 93 Packard CJ, Bell MA, Eaton RH, Dagen MM, Cassidy M, Shepherd J. A pilot scheme for improving the accuracy of serum cholesterol measurement in Scotland and Northern Ireland. Ann Clin Biochem 1993; 30: 387–93.
- 94 Broughton PMG, Bullock DG, Cramb R. Quality of plasma cholesterol measurements in primary care. Br Med J 1989; 298: 297–8.
- 95 Neil HAW, Cassidy DM, Laker MF, Alberti KGMM. Within-clinic reagent strip measurement. Diabet Med 1989; 6: 824–8.
- 96 Friedlander Y, Kark JD, Stein Y. Biological and environmental sources of variation in plasma lipids and lipoproteins: the Jerusalem lipid research clinic. Hum Hered 1986; 36: 143–53.
- 97 Mogadam M, Ahmed SW, Mensch AH, Godwin ID. Within-person fluctuations of serum cholesterol and lipoproteins. Arch Intern Med 1990; 150: 1645–8.
- 98 Thompson SG, Pocock SJ. The variability of serum cholesterol measurements: implications for screening and monitoring. J Clin Epidemiol 1990; 43: 783–9.
- 99 Jones PJH, Schoeller DA. Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res 1990; 31: 667–73.
- 100 Terpstra J, Hessel LW, Seepers J, van Gent CM. The influence of meal frequency on diurnal lipid, glucose and cortisol levels in normal subjects. Eur J Clin Invest 1978; 8: 61–6.
- 101 Robinson D, Bevan EA, Hinohara S, Takahashi T. Seasonal variation in serum cholesterol levels evidence from the UK and Japan. Atherosclerosis 1992; 95: 15–24.
- 102 Gordon DJ, Trost DC, Hyde J, Whaley FS, Hannan PJ, Jacobs DR Jr, et al.Seasonal cholesterol cycles: the Lipid Research Clinics Primary Coronary Prevention Trial Placebo Group. Circulation 1987; 76: 1224–31.
- 103 Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979; 60: 427–39.
- 104 Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G, et al.Lipoprotein-cholesterol distributions in selected North American populations; the Lipid Research Clinics Program Prevalence Study. Circulation 1980; 61: 302–15.
- 105 Low-Beer TS, Wicks ACB, Heaton KW, Durrington P, Yeates J. Fluctuations of serum and bile lipid concentrations during the menstrual cycle. Br Med J 1977; 1: 1568–70.
- 106 Hemer HA, deBourges VV, Ayala JJ, Brito G, Dýáz-Sánchez V, Garza-Flores J. Variations in serum lipids and lipoproteins throughout the menstrual cycle. Fertil Steril 1985; 44: 80–4.
- 107 Fåhraeus L, Larsson-Cohn U, Wallentin L. Plasma lipoproteins including high density lipoprotein subfractions during normal pregnancy. Obstet Gynecol 1985; 66: 468–72.
- 108 Rosing U, Samsioe G, Ölund A, Johansson B, Kallner A. Serum levels of apolipoprotein A-I, A-II and HDL-cholesterol in second half of normal pregnancy and in pregnancy complicated by pre-eclampsia. Horm Metab Res 1989; 21: 376–82.
- 109 Mann JI, Truswell AS. Effect of controlled breakfast on serum cholesterol and triglycerides. Am J Clin Nutr 1971; 24: 1300.
- 110 Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990; 31: 1149–72.
- 111 Edelstein SL, Barrett-Connor EL, Wingard DL, Cohn BA. Increased meal frequency associated with decreased cholesterol concentrations; Rancho Bernardo, CA, 1984–1987. Am J Clin Nutr 1992; 55: 664–9.
- 112 Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988; 29: 469–79.
- 113 Rifai N, Merrill JR, Holly RG. Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements. Ann Clin Biochem 1990; 27: 489–93.
- 114 Markel A, Brook JG, Aviram M. Increased plasma triglycerides, cholesterol and apolipoprotein E during prolonged fasting in normal subjects. Postgrad Med J 1985; 61: 395–400.
- 115 Pietinen P, Aro A, Tuomilehto J, Uusitalo U, Korhonen H. Consumption of boiled coffee is correlated with serum cholesterol in Finland. Int J Epidemiol 1990; 19: 586–90.
- 116 Stensvold I, Tverdal A, Foss OP. The effect of coffee on blood lipids and blood pressure. Results from a Norwegian cross-sectional study, men and women, 40–42 years. J Clin Epidemiol 1989; 42: 877–84.
- 117 Ahola I, Jauhiainen M, Aro A. The hypercholasterolaemic factor in boiled coffee is retained by a paper filter. J Intern Med 1991; 230: 293–7.
- 118 vanDusseldorp M, Katan MB, vanVliet T, Demacker PNM, Stalenhoef AFH. Cholesterol-raising factor from boiled coffee does not pass a paper filter. Arterioscler Thromb 1991; 11: 586–93.
- 119 Aro A, Teirilä J, Gref C-G. Dose-dependent effect on serum cholesterol and apoprotein B concentrations by consumption of boiled, non-filtered coffee. Atherosclerosis 1990; 83: 257–61.
- 120 Zock PL, Katan MB, Merkus MP, vanDusseldorp M, Harryvan JL. Effect of a lipid-rich fraction from boiled coffee on serum cholesterol. Lancet 1990; 335: 1235–7.
- 121 Castelli WP, Gordon T, Hjortland MC, Kagan A, Doyle JT, Hames CG, et al.Alcohol and blood lipids. Lancet 1977; 2: 153–5.
- 122 Gordon T, Ernst N, Fisher M, Rifkind BM. Alcohol and high-density lipoprotein cholesterol. Circulation 1981; 64 (suppl III): 63–7.
- 123 Veenstra J, Ockhuizen T, van de Pol H, Wedel M, Schaafsma G. Effects of a moderate dose of alcohol on blood lipids and lipoproteins postprandially and in the fasting state. Alcohol 1990; 25: 371–7.
- 124 Booth S, Clifton PM, Nestel PJ. Lack of effect of acute alcohol ingestion on plasma lipids. Clin Chem 1991; 37: 1649.
- 125 Ginsberg H, Olefsky J, Farquhar JW, Reaven GM. Moderate ethanol ingestion and plasma triglyceride levels. A study in normal and hypertriglyceridemic persons. Ann Intern Med 1974; 80: 143–9.
- 126 Wolfe BM, Havel RJ, Marliss EB, et al.Effects of a three-day fast and of ethanol on splanchnic metabolism of free fatty acids, amino acids and carbohydrates in healthy young men. J Clin Invest 1976; 57: 329–40.
- 127 Superko HR. Effects of acute and chronic alcohol consumption on postprandial lipemia in healthy normotriglyceridemic men. Am J Cardiol 1992; 69: 701–4.
- 128 Taskinen M-R, Nikkilä EA, Välimäki M, Sane T, Kuusi T, Kesäniemi YA, et al.Alcohol-induced changes in serum lipoproteins and their metabolism. Am Heart J 1987; 113: 458–64.
- 129 Wood PD, Haskell WL. The effect of exercise on plasma high density lipoproteins. Lipids 1979; 14: 417–27.
- 130 Marti B, Suter E, Riesen WF, Tschopp A, Wanner HU, Gutzwiller F. Effects of long-term, self-monitored exercise on the serum lipoprotein and apolipoprotein profile in middle-aged men. Atherosclerosis 1990; 81: 19–31.
- 131 Pay HE, Hardman AE, Jones GJ, Hudson A. The acute effects of low-intensity exercise on plasma lipids in endurance trained and untrained young adults. Eur J Appl Physiol 1992; 64: 182–6.
- 132 Krum H, Conway EL, Howes LG. Acute effects of exercise on plasma lipids, noradrenaline levels and plasma volume. Clin Exp Pharmacol Physiol 1991; 18: 697–701.
- 133 Burkman RT. Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy. Fertil Steril 1988; 49 (suppl): 39S–50S.
- 134 Crook D, Seed M. Endocrine control of plasma lipoprotein metabolism: effects of gonadal steroids. Clin Endocrinol Metab 1990; 4: 851–75.
- 135 Upton GV. Lipids, cardiovascular disease, and oral contraceptives: a practical perspective. Fertil Steril 1990; 53: 1–12.
- 136 Lussier-Cacan S, Xhignesse M, Desmarais J-L, Davignon J, Kafrissen ME, Chapdelaine A. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy. Metabolism 1991; 40: 849–54.
- 137 Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehaed MI, Wynn V. Comparison of transdermal and oral estrogen–progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166: 950–5.
- 138 Mattson LÅ, Samsioe G, vonSchoultz B, Uverbrant M, Wilkund I. Transdermally administered oestradiol combined with oral medroxyprogesterone in postmenopausal women. Br J Obstet Gynaecol 1993; 100: 450–3.
- 139 Kuritzes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J Med 2003; 348: 679–80.
- 140 Lindenmayer J-P,Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lierberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychol 2003; 160: 290–6.
- 141 Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in serum triglycerides. Am J Psychol 1999; 156: 1270–2.
- 142 Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche H-U, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporin combination regimen for renal transplantation. Transplantation 1998; 66: 1040–6.
- 143 Ahnve S, Angelin B, Edhag O, Berglund L. Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention. J Intern Med 1989; 226: 297–301.
- 144 Sewdarsen M, Vythilingum S, Jialal I, Nadar R. Plasma lipids can be reliably assessed within 24 hours after acute myocardial infarction. Postgrad Med J 1988; 64: 352–6.
- 145 Ryder REJ, Hayes TM, Mulligan IP, Kingswood JC, Williams S, Owens DR. How soon after myocardial infarction should plasma lipid values be assessed? Br Med J 1984; 289: 1651–3.
- 146 Avogaro P, Bittolo Bon G, Cazzolato G, Quinci GB, Sanson A, Sparla M, et al.Variations in apolipoproteins B and A1 during the course of myocardial infarction. Eur J Clin Invest 1978; 8: 121–9.
- 147 Fahie-Wilson M, Mills R, Wilson K. HDL cholesterol and the acute phase reaction following myocardial infarction and acute pancreatitis. Clin Chim Acta 1987; 167: 197–209.
- 148 Sammalkorpi K, Valtonen V, Kerttula Y, Nikkilä E, Taskinen M-R. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988; 37: 859–65.
- 149 Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985; 135: 3969–71.
- 150 Patton JS, Shepard HM, Wilking H, Lewis G, Aggarwal BB, Eessalu TE, et al.Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci USA 1986; 83: 8313–7.
- 151 Alvarez C, Ramos A. Lipids, lipoproteins and apoproteins in serum during infection. Clin Chem 1986; 32: 142–5.
- 152 Lindh A, Lindholm M, Holmquist L, Carlson LA. Time course for the changes of serum lipoproteins and apolipoprotein T concentrations after major surgical trauma in man. J Parent Enter Nutr 1986; 10: 265–73.
- 153 Coombes EJ, Shakespeare PG, Batstone GF. Lipoprotein changes after burn injury in man. J Trauma 1980; 20: 971–5.
- 154 Harris RL, Frenkel RA, Cottam GL, Baxter CR. Lipid mobilisation and metabolism after thermal trauma. J Trauma 1982; 22: 194–8.
- 155 Kritchevsky SB, Wilcosky TC, Morris DL, Truong KN, Tyroler HA. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 1991; 51: 3198–203.
- 156 Sherwin RW, Wentworth DN, Cutler JA, Hulley SB, Kuller LH, Stamler J. Serum cholesterol levels and cancer mortality in 361 662 men screened for the Multiple Risk Factor Intervention Trial. J Am Med Assoc 1987; 257: 943–8.
- 157 Gerhardsson M, Rosenqvist U, Ahlbom A, Carlson L. Serum cholesterol and cancer a retrospective casecontrol study. Int J Epidemiol 1986; 15: 155–9.
- 158 Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 1991; 2: 253–61.
- 159 Miller M, Bachorik PS, Cloey TA. Normal variation of plasma lipoproteins: postural effects on plasma concentrations of lipids, lipoproteins, and apolipoproteins. Clin Chem 1992; 38: 569–74.
- 160 Tan MH, Wilmshurst EG, Gleason RE, Soeldner JS. Effect of posture on serum lipids. N Engl J Med 1973; 289: 416–19.
- 161 Howes LG, Krum H, Louis WJ. Plasma cholesterol levels are dependent on sympathetic activity. J Hypertens 1987; 5 (suppl 5): S361–3.
- 162 Dixon M, Paterson CR. Posture and the composition of plasma. Clin Chem 1978; 24: 824–6.
- 163 Felding P, Tryding N, Hyltoft Petersen P, Horder M. Effects of posture on concentrations of blood constituents in healthy adults: practical application of blood specimen collection procedures recommended by the Scandinavian Committee on Reference Values. Scand J Clin Lab Invest 1980; 40: 615–21.
- 164 Eisenberg S. Postural changes in plasma volume in hypoalbuminemia. Arch Intern Med 1963; 112: 544–9.
- 165 Page IH, Moinuddin M. The effect of venous occlusion on serum cholesterol and total protein concentration a warning. Circulation 1962; 25: 651–2.
- 166 Koerselman HB, Lewis B, Pilkington TRE. The effect of venous occlusion on the level of serum cholesterol. J Atheroscler Res 1961; 1: 85–8.
- 167 Sperry WM, Schoenheimer R. A comparison of serum, heparinised plasma, and oxalated plasma in regard to cholesterol content. J Biol Chem 1935; 110: 655–8.
- 168 Grande F, Amatuzio DS, Wada S. Cholesterol measurement in serum and in plasma. Clin Chem 1964; 10: 619–26.
- 169 Alper C. Specimen collection and preservation. In RJ Henry, DC Cannon, JW Winkelman (eds), Clinical Chemistry: Principles and Technics. New York: Harper & Row, 1974; pp 373–88.
- 170 Cloey T, Bachorik PS, Becker D, Finney C, Lowry D, Sigmund W. Re-evaluation of serum–plasma differences in total cholesterol concentration. J Am Med Assoc 1990; 263: 2788–9.
- 171 Ladenson JH, Tsai L-MB, Michael JM, Kessler G, Joist JH. Serum versus heparinised plasma for eighteen common chemistry tests. Is serum the appropriate specimen? Am J Clin Pathol 1974; 62: 545–52.
- 172 Laboratory Methods Committee. Cholesterol and triglyceride concentrations in serum/plasma pairs. Clin Chem 1977; 23: 60–3.
- 173 National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36–69.
- 174 Kuchmak M, Taylor L, Olansky AS. Suitability of frozen and lyophilised reference sera for cholesterol and triglyceride determinations. Clin Chim Acta 1982; 120: 261–71.
- 175 Reckless JPD, Betteridge DJ, Wu P, Payne B, Galton DJ. Effect of storage on plasma-lipoproteins. Lancet 1977; 2: 350.
- 176 Stokes YM, Salmond CE, Carpenter LM, Welby TJ. Stability of total cholesterol, high-density-lipoprotein cholesterol, and triglycerides in frozen sera. Clin Chem 1986; 32: 995–9.
- 177 Warnick GR, Albers JJ. High-density-lipoprotein cholesterol quantitation: effect of plasma storage on heparin-Mn2+ supernanant cholesterol concentration. Clin Chem 1979; 25: 1098–9.
- 178 Bachorik PS, Walker R, Brownell KD, Stunkard AJ, Kwiterovich PO. Determination of high density lipoprotein-cholesterol in stored human plasma. J Lipid Res 1980; 21: 608–16.
- 179 Bachorik PS, Walker RE, Kwiterovich PO Jr. Determination of high density lipoprotein-cholesterol in human plasma stored at −70°C. J Lipid Res 1982; 23: 1236–42.
- 180 Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, Kaplan LA, et al.Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 1989; 35: 2313–6.
- 181 delGatto L, Nichols AV, Lindgren FT. Effects of freeze-thawing and storage on ultracentrifugal properties of human serum lipoproteins. Proc Soc Exp Biol Med 1959; 101: 59–61.
- 182 Tiedink HGM, Katan MB. Variability in lipoprotein concentrations in serum after prolonged storage at −20°C. Clin Chim Acta 1989; 180: 147–56.
- 183 Winkelman J, Wybenga DR, Ibbott FA. Phenotyping of hyperlipoproteinaemias. Clin Chem 1970; 16: 507–11.